OPEN VOOR INCLUSIE
PEGASUS- A Phase 2, Randomized, Open-label, 3-arm Study to Assess the Efficacy and Safety of relacorilant in Combination with Nab-paclitaxel for Patients with Platinum-resistant Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.
ENGOT-cx11/MK3475-A18- A randomized, phase 3, double-blind study of chemoradiotherapy with or without Pembrolizumab for the treatment of high-risk, locally advanced cervical cancer
EORTC1740- Randomized Phase II study of Cisplatin plus Radiotherapy versus Durvalumab plus Radiotherapy followed by Maintenance Durvalumab versus Durvalumab plus Radiotherapy followed by Maintenance Tremelimumab and Durvalumab in Intermediate Risk HPV-Positive Locoregionally Advanced Oropharyngeal Squamous Cell Cancer
DEBIO 1143-301- A randomized, double-blind placebo-controlled, Phase 3 study of Debio 1143 in combination with platinum-based chemotherapy and standard fractionation intensity-modulated radiotherapy in patients with locally advanced squamous cell carcinoma of the head and neck, suitable for definitive chemoradiotherapy (TrilynX).
SAVE- A Phase II randomized, open-label study comparing salvage radiotherapy in combination with 6 months of andorgen-deprivation therapy (ADT) with LHRH agonist or antagonist versus anti-androgen therapy (AAT) with apalutamide in patients with biochemical progression after radical prostatectomy.
DOSIS RCT-SPINE SBRT- Dose intensified Image-guided fractionated Stereotactic body radiation therapy for painful spinal metastases versus conventional radiation therapy: a phase II randomised controlled trial
GESLOTEN VOOR INCLUSIE
EORTC1709- A phase III trial of marizomib in combinaton with standard temozolomide-base radiochemotherapy vs standard temozolomide-base radiochemotherapy alone in patients with newly diagnosed glioblastoma.
ATLAS - 56021927PCR3003- A Randomized, Double-blind, Placebo-controlled Phase 3 Study of JNJ-56021927 in Subjects with High-risk, Localized or Locally Advanced Prostate Cancer Receiving Treatment with Primary Radiation Therapy